UK markets closed

BioInvent International AB (publ) (0H22.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
44.540.00 (0.00%)
At close: 04:13PM GMT

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
46 4 62 86 85 50

Full-time employees93

Key executives

NameTitlePayExercisedYear born
Dr. Martin Welschof Ph.D.Pres & CEO4.75MN/A1961
Mr. Stefan Ericsson M.B.A.Chief Financial OfficerN/AN/A1963
Ms. Marie Moores M.Sc., R.G.N.Chief Operating OfficerN/AN/AN/A
Mr. Kristoffer Rudenholm HanssonSr. VP of Technical OperationsN/AN/A1974
Mr. Björn FrendéusChief Scientific OfficerN/AN/A1973
Ms. Cecilia HofvanderSr. Director of Investor RelationsN/AN/A1967
Dr. Andres McAllisterChief Medical OfficerN/AN/A1956
Ms. Ingrid TeigeHead of Preclinical ResearchN/AN/AN/A
Ms. Sylvie RyckebuschChief Bus. OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.


BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Corporate governance

BioInvent International AB (publ)’s ISS governance QualityScore as of 1 November 2022 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.